Seeking Alpha

Abraxix

Abraxix
Send Message
View as an RSS Feed
View Abraxix's Comments BY TICKER:
Latest  |  Highest rated
  • The Instructive Case Of Galena Biopharma [View article]
    ""Momentum" investing is a fancy name for "I'm buying this because it's going up""

    Oh gee, so I guess Apple stock going up from $5.00 to $500 is because investors are, in your words, "stupid and greedy"?

    The Dream Team project was coincidental to the momentum in Galena. The real factor for investor interest in Galena came from the Mills purchase and Abstral rights.
    Feb 26, 2014. 10:35 AM | 15 Likes Like |Link to Comment
  • Galena Biopharma: The Oncologist's Perspective On A Life Saving Therapy [View article]
    "like a Judas you served your Intended Purpose for your 30 pieces of Silver and like a Judas one day you will likely be found a fixed to some tree..."

    Matt is laughing at you.
    Feb 24, 2014. 10:26 AM | 1 Like Like |Link to Comment
  • Galena Biopharma: Numerous Red Flags Suggest A Significant Overvaluation [View article]
    "Just simply responding to a comment there Sherlock..."

    Since you are posing as having clean hands, tell us if your position in Galena has changed at any point since you wrote your article, and furthermore, if your interests in Galena changed, then please explain how?
    Feb 22, 2014. 04:40 PM | 1 Like Like |Link to Comment
  • Galena Biopharma: Numerous Red Flags Suggest A Significant Overvaluation [View article]
    "Please tell me this is a joke. Did you actually look at the details? You are 100% wrong."

    Why are are citing a dose escalation safety trial, dated from before 2006? Has nothing to do with the later booster program trial that has PROVEN CLINICAL EFFICACY.

    But of course you know that. You also know that by carping on anything except the results of the booster program, you are lighting the fuse of doubt. I know you are not an idiot, so can only surmise you are duplicitous.
    Feb 22, 2014. 11:02 AM | 2 Likes Like |Link to Comment
  • Why Groupon Tanked And Might Continue To Do So [View article]
    Ebay NEEDS to buy Groupon.
    Feb 21, 2014. 03:57 PM | 1 Like Like |Link to Comment
  • Why Groupon Tanked And Might Continue To Do So [View article]
    Shane, I also spotted the quarter over quarter argument and was going to comment. Does anyone have granularity on the seasonality of Groupon's numbers?
    Feb 21, 2014. 12:47 PM | 1 Like Like |Link to Comment
  • Galena Biopharma: The Oncologist's Perspective On A Life Saving Therapy [View article]
    "The demographics of the phase II trial, coupled with the SPA defined endpoints/protocol for the phase III trial, suggest that a 30% benefit in disease free survival will not be achieved."

    More lies............the control group is healthier than the VG. Look up prognostics of HLA-A1/A2+ (positive) as compared to HLA-A1/A2- (negative).
    Feb 20, 2014. 05:50 PM | Likes Like |Link to Comment
  • The Least Understood Dynamic In Today's Economy And What It Means For Investment Assets [View article]
    I want carbon credits to be the world reserve currency.
    Feb 20, 2014. 01:48 AM | 1 Like Like |Link to Comment
  • Galena Biopharma Issues Letter To Shareholders, And A Case Of Insider Seller's Remorse [View article]
    Bryce , that was a typo. Meant to write "P value under .05" in the booster subset.

    In fact it was .04 as per your link at 11:39.

    The difference between control and VG----HLA-A2/A3 negative was the control and HLA-A2/A3 positive was the vaccinated group. There is precedence for this trial design however:

    http://1.usa.gov/1mc7b28

    Although HLA type is not considered prognostic for recurrence, there is evidence that HLA-A2/A3 positive patients fare worse:

    "None of the HLA-A2 positive patients survived 5 years, compared to more than 50% of the HLA-A2 negative patients"

    So when the short agenda states that the VG was healthier, they lie.
    Feb 20, 2014. 12:40 AM | Likes Like |Link to Comment
  • Galena Biopharma: The Oncologist's Perspective On A Life Saving Therapy [View article]
    Thankyou, Dr. Farhat.

    Gravitt, Feuerstein and his associates, are market clowns.
    Feb 19, 2014. 07:08 PM | 26 Likes Like |Link to Comment
  • Galena Biopharma Issues Letter To Shareholders, And A Case Of Insider Seller's Remorse [View article]
    "I feel like I have a handle on the science of Neuvax now and it looks good. Physicians and those with a medical background generally seem to agree."

    The science is rock solid, I had this discussion many months ago with Dr. Schwartz who contributed a negative article on SA. Here's the thing, the Phase 2 sub-cohort, optimally dosed, was compared against a control that was a slightly different HLA haplotype. Even though the P value was under 5 for this study, Dr. Schwartz, a biochemist by training, felt it violated protocol by measuring against a dissimilar control. However, contrary to the misinformation disseminated by Feuerstein (and other market terrorists), the control haplotype was actually healthier than the vaccinated group, less prone to recurrence.

    Even so, purists, and by this I mean by-the-book biochemical researchers, will not invest in Galena because of the discrepancy. There is cultural friction between clinicians who run studies, like Dr. Peoples, and biochemists who run studies from their labs. I put my money on clinicians like Dr. Peoples every time, they have a better handle on emergence (sic) issues.

    I am hoping that SA contributor Brian Nichols will come out with a paper that clears up a lot of the absolute rubbish that has been spewed here by the short agenda. Regarding the recent run up in stock price, I believe it had more to do with the prospects for Abstral and the Mills Pharmacy purchase. I read the articles that the DreamTeam put out (did not know the source at the time) and I dismissed them as obvious fluff pieces. Anyone who made an investment decision based on DreamTeam product has to be soft in the head.
    Feb 19, 2014. 06:43 PM | 1 Like Like |Link to Comment
  • Galena Biopharma Issues Letter To Shareholders, And A Case Of Insider Seller's Remorse [View article]
    "my back of the envelop calculation was 2.8 million shares sold at an average of $5.40 (roughly), i.e. $ 15.26 million "

    What envelope, your monthly bill for Acme Boiler Room? Subtract roughly 15% for cost of exercising the options and the $15.26 is reduced to $12.85 million. Then divide that by the six company insiders who exercised these options and you get roughly $2.142 million per director. Then divide that by 3 for the three years of work that award represents and you come out with payment of $714,000 per year per director. That is a pretty pitiful paycheck for the ROI that shareholders got for it.
    Feb 18, 2014. 01:17 PM | Likes Like |Link to Comment
  • A Deeper Look At The Galena Biopharma Controversy [View article]
    Dr. Peoples sound bites here:

    http://bit.ly/1dVWz0F
    Feb 16, 2014. 02:56 PM | 2 Likes Like |Link to Comment
  • Galena Biopharma: Numerous Red Flags Suggest A Significant Overvaluation [View article]
    "Can you respond to this, Matt?"

    You wont get self reflection from some schmuck who bombs peoples portfolios with scurrilous disinformation. Any moron can become a bomber, it takes no skill whatsoever, which is why there are a lot of these predatory characters in finance. Besides, though he will deny it, Matt is probably long Galena now.
    Feb 14, 2014. 10:04 PM | 1 Like Like |Link to Comment
  • Galena: Read, Decide, Invest [View article]
    Consider why Galena was forced into this strategy (hiring a public relations firm). Over a year ago, quite favorable media reports were being generated because of the very promising vaccine science Galena was pursuing. The Phase III program excited a lot of interest among families of breast cancer survivors. Interviews with Dr. People's and his patients began appearing in the press. Galena became high profile and an attractive target to short attacks---That is to say, Galena was now a battleground stock. It was a small company with a great vaccine and small float--- the perfect situation for manipulating the vols. That was when the Fudsters started crawling out of the woodwork. Propthink was not the first, I forget the names of the others who preceded that nest of low lifes. So rather than letting itself be pushed around by the gutter tactics of Wall Street, Galena hired some Street talent of its own to fight off the goons. Good for them!

    Any moron can cause a sensation by tossing a bomb of FUD in a crowded market place and then dash in to sweep up the change that falls out of the pockets of the retail investors. It takes work and discipline, however, to build a capitalist structure that serves some human need.
    Feb 14, 2014. 12:02 AM | 6 Likes Like |Link to Comment
COMMENTS STATS
345 Comments
505 Likes